Online inquiry

IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9042MR)

This product GTTS-WQ9042MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets FLT1 gene. The antibody can be applied in Colon Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001159920.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2321
UniProt ID P17948
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9042MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12126MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MORAb-003
GTTS-WQ12475MR IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA NN-8226
GTTS-WQ1648MR IVTScrip™ mRNA-Anti-GP6, ACT-017(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ACT-017
GTTS-WQ8503MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA hu1124
GTTS-WQ12088MR IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MOR-03087
GTTS-WQ12610MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA NVS250519
GTTS-WQ4487MR IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-931699
GTTS-WQ6578MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA DC-1630423
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW